Korean J Gastroenterol.  2019 Mar;73(3):121-123. 10.4166/kjg.2019.73.3.121.

Curative Loco-regional Therapies for Early Hepatocellular Carcinoma: Is Combination Effective?

• Lee SH

• KMID: 2442077
• DOI: http://doi.org/10.4166/kjg.2019.73.3.121

Abstract

No abstract available.

MeSH Terms

Carcinoma, Hepatocellular*

Reference

1. Li L, Zhao W, Wang M, et al. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2018; 18:138.

2. Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69:182–236.

3. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012; 107:569–577. quiz 578.

4. Liu Z, Gao F, Yang G, et al. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. Tumour Biol. 2014; 35:7407–7413.

5. Wang X, Hu Y, Ren M, Lu X, Lu G, He S. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis. Korean J Radiol. 2016; 17:93–102.

6. Choe WH, Kim YJ, Park HS, Park SW, Kim JH, Kwon SY. Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol. 2014; 20:12588–12594.

7. Wang WD, Zhang LH, Ni JY, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for hepatocellular carcinoma within the Milan criteria: a meta-analysis. Korean J Radiol. 2018; 19:613–622.

8. Kim AR, Park E, Kwon SY, et al. Efficacy and safety of combined radiofrequency ablation with transarterial chemoembolization in patients with BCLC stage A hepatocellular carcinoma ineligible for curative treatment. Korean J Gastroenterol. 2019; 73:167–176.

9. Chen R, Geschwind JF, Wang Z, Tacher V, Lin M. Quantitative assessment of lipiodol deposition after chemoembolization: comparison between cone-beam CT and multidetector CT. J Vasc Interv Radiol. 2013; 24:1837–1844.

10. Ishikawa T, Abe S, Hoshii A, et al. Cone-beam computed tomography correlates with conventional helical computed tomography in evaluation of lipiodol accumulation in HCC after chemoembolization. PLoS One. 2016; 11:e0145546.

11. Jun BG, Kim SG, Kim YD, et al. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: propensity score matching analysis. PLoS One. 2018; 13:e0206381.

12. Paik EK, Kim MS, Jang WI, et al. Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. Radiat Oncol. 2016; 11:22.

13. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan society of hepatology (JSH) 2010 updated version. Dig Dis. 2011; 29:339–364.